Increased Sensitivity of Detection of
DNA methylation
cancer diagnostics
cell-free tumour DNA
circulating cell-free DNA (cfDNA)
digital PCR
liquid biopsy
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Sep 2021
04 Sep 2021
Historique:
received:
07
07
2021
revised:
01
09
2021
accepted:
02
09
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Identification of aberrant DNA methylation is a promising tool in prostate cancer (PCa) diagnosis and treatment. In this study, we evaluated a two-step method named optimised bias-based preamplification followed by digital PCR (OBBPA-dPCR). The method was used to identify promoter hypermethylation of 2 tumour suppressor genes
Identifiants
pubmed: 34503269
pii: cancers13174459
doi: 10.3390/cancers13174459
pmc: PMC8431466
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bundesministerium für Bildung und Forschung (BMBF); Forschungszentrum Jülich GmbH
ID : 031B0098C; 03WKDB2G
Références
N Engl J Med. 2009 Mar 26;360(13):1310-9
pubmed: 19297565
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
pubmed: 8790415
Sci Rep. 2020 Jun 3;10(1):9058
pubmed: 32493972
Curr Mol Med. 2007 Feb;7(1):85-102
pubmed: 17311535
Oncogene. 2002 Oct 3;21(44):6835-40
pubmed: 12360410
Cancers (Basel). 2020 Oct 15;12(10):
pubmed: 33076494
Front Genet. 2014 Oct 21;5:341
pubmed: 25374580
Oncotarget. 2018 Nov 16;9(90):36137-36150
pubmed: 30546833
J Urol. 2017 Feb;197(2S):S200-S207
pubmed: 28012755
J Urol. 2013 Mar;189(3):1110-6
pubmed: 22999998
Epigenomics. 2010 Aug;2(4):561-73
pubmed: 22121974
Biotechniques. 2013 Oct;55(4):181-97
pubmed: 24107250
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7
pubmed: 7972132
Clin Chem Lab Med. 2018 Apr 25;56(5):702-717
pubmed: 29305565
Biochim Biophys Acta. 2007 Jun;1770(6):847-56
pubmed: 17368950
JAMA. 1998 May 20;279(19):1542-7
pubmed: 9605898
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Kaohsiung J Med Sci. 2015 Jun;31(6):315-9
pubmed: 26043411
Urology. 2002 Nov;60(5):836-40
pubmed: 12429311
Cancer Res. 2016 Mar 15;76(6):1367-80
pubmed: 26759232
Gynecol Oncol. 2017 Sep;146(3):603-608
pubmed: 28669560
N Engl J Med. 2009 Mar 26;360(13):1320-8
pubmed: 19297566
Eur Urol. 2012 Dec;62(6):997-8; discussion 999-1000
pubmed: 22871359
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
Nucleic Acids Res. 2011 Jun;39(11):e77
pubmed: 21486748
BMC Cancer. 2009 Dec 21;9:453
pubmed: 20025721
N Engl J Med. 2008 Mar 13;358(11):1148-59
pubmed: 18337604
Clin Chem. 2009 Aug;55(8):1471-83
pubmed: 19520761
J Urol. 2014 Dec;192(6):1849-55
pubmed: 24980613
Mol Biotechnol. 2010 Jan;44(1):71-81
pubmed: 19842073
Nat Rev Cancer. 2003 Apr;3(4):253-66
pubmed: 12671664
Ann N Y Acad Sci. 2008 Aug;1137:218-21
pubmed: 18837950
Curr Opin Clin Nutr Metab Care. 2007 Sep;10(5):576-81
pubmed: 17693740
JAMA. 1997 May 14;277(18):1452-5
pubmed: 9145717
Mol Oncol. 2020 Nov;14(11):2920-2935
pubmed: 32813937
Mol Ther Nucleic Acids. 2020 Jun 5;20:50-61
pubmed: 32146418
N Engl J Med. 2003 Jul 17;349(3):215-24
pubmed: 12824459
Oncol Rep. 2012 May;27(5):1630-8
pubmed: 22159596
Cancer Cell Int. 2020 Nov 10;20(1):547
pubmed: 33292241
EBioMedicine. 2017 Apr;18:32-40
pubmed: 28396012
Bangladesh Med Res Counc Bull. 2012 Dec;38(3):90-3
pubmed: 23540183
J Cancer Res Ther. 2017 Apr-Jun;13(2):279-283
pubmed: 28643748
Br J Cancer. 1993 Jan;67(1):66-70
pubmed: 8427781
Oncotarget. 2017 Feb 28;8(9):15431-15440
pubmed: 28147335